Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist.It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).[1][2][3].
Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals.
Next came a dual GLP-1/GIP receptor agonist, tirzepatide, marketed under the brand name Zepbound, which was approved for obesity in 2023. Both medications are administered by injection. The end of 2025 brought the first oral GLP-1 RA medication for obesity treatment...
The effectiveness of GLP- 1 and dual GLP- 1/GIP receptor agonists in the treatment of obesity and overweight has been thoroughly established [143].For patients with T2DM and obesity, GLP- 1 receptor agonists offer hope for better outcomes and a higher quality of life.
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine.
Furthermore, visual representations like the one above help us fully grasp the concept of Glp-1 And Glp-2 Agonists For Obesity.
A promising area of research involves GLP-1 agonists, medications traditionally prescribed for type 2 diabetes and obesity. These medications can promote feelings of fullness, reduce appetite, and support healthier eating habits, facilitating weight management.
Theres a good chance that, as we have more patients who get GLP-1 agonists for obesity, we might find similar results, Thosani says.
